E. De Stanchina

TL;DR: DNA methylation patterns of primary samples are distinct from those of cell lines, whereas PDX maintain a pattern closely consistent with primary samples, revealing distinct disease subtypes among histologically indistinguishable primary patient samples with similar genetic alterations.

TL;DR: Genetic alterations that co-occur with oncogenic BRAF in melanoma and abrogate cellular dependence upon this oncogene provide a genetic basis for the heterogeneity of clinical outcomes in patients treated with targeted inhibitors of the mitogen-activated protein kinase pathway.

TL;DR: HAC3 inhibition represents a novel mechanism-based immune-epigenetic therapy for CREBBP mutant lymphomas and restored the ability of tumor infiltrating lymphocytes to kill DLBCL cells in an MHC class I and II dependent manner.

TL;DR: By reactivating these genes, exposure to HDAC3-i restored the ability of tumor infiltrating lymphocytes to kill DLBCL cells in an MHC II and MHC I dependent manner, and represents a novel mechanism-based immune-epigenetic therapy for CREBBP mutant lymphomas.

TL;DR: In this paper, the authors report a scTCR/RNA-seq dataset of 162,062 single T cells from 31 tissue regions, including tumor, adjacent normal tissues, and lymph nodes (LN), from three patients who underwent resections for progressing lung cancers after immune checkpoint blockade (ICB).